Excellent news, the label approved by the FDA was just about as broad as could have been hoped for and now CMS coverage follows.
So many doors now open in the AD sector, starting with Donanemab and many other therapeutics working their way through the pipeline. We then also have registration trials, optimisation trials, trials for reformulations, trials for easier delivery methods (subcutaneous), combination trials and all the while as we get better at treatment we need to be able to triage those in the community on to formal diagnostic pathways and treatment. All in all plenty of demand for Cogstate to capture and no one better placed in the AD space.
All of this also improves the chance of takeover talks resuming
Good news, page-8
-
- There are more pages in this discussion • 2 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add CGS (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.08 |
Change
-0.040(3.59%) |
Mkt cap ! $186.1M | |||
| Open | High | Low | Value | Volume |
| $1.12 | $1.12 | $1.07 | $90.89K | 83.15K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 2757 | $1.08 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.08 | 4637 | 3 |
View Market Depth
| Last trade - 12.27pm 25/06/2024 (20 minute delay) ? |
| CGS (ASX) Chart |